Literature DB >> 10835498

Ras and signal transducer and activator of transcription (STAT) are essential and sufficient downstream components of Janus kinases in cell proliferation.

R Mizuguchi1, S Noto, M Yamada, S Ashizawa, H Higashi, M Hatakeyama.   

Abstract

Cytokines exert their activities in cell growth and differentiation by binding specific cell membrane receptors. Janus kinases (JAKs) are cytoplasmic protein tyrosine kinases that physically interact with intracellular domains of the cytokine receptors and they play crucial roles in transducing signals triggered by the cytokine-receptor interaction. We have previously shown that conditional activation of JAK through membrane-proximal dimerization confers cytokine-independence on interleukin-3 (IL-3)-dependent Ba / F3 lymphoid cells and that the cytokine-independent proliferation is completely inhibited by dominant negative Ras. In this work, we demonstrate that ectopic expression of a dominant negative form of Stat5, a major signal transducer and activator of transcription (STAT) expressed in Ba / F3 cells, also inhibits JAK-triggered mitogenesis. In contrast, overexpression of constitutively active Ras or conditional activation of Stat5 by chemical dimerization fails to confer cytokine-independence. However, concomitant activation of ectopic Ras and Stat5 molecules in Ba / F3 cells suffices for cell proliferation in the absence of IL-3. Our results indicate that Ras and STAT are essential and sufficient components of JAK-triggered mitogenesis. Our findings further indicate that the cytokine signal bifurcates into Ras and STAT pathways following JAK activation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10835498      PMCID: PMC5926385          DOI: 10.1111/j.1349-7006.2000.tb00977.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  36 in total

1.  Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1.

Authors:  H Aktas; H Cai; G M Cooper
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

Review 2.  Cytokine signaling through nonreceptor protein tyrosine kinases.

Authors:  T Taniguchi
Journal:  Science       Date:  1995-04-14       Impact factor: 47.728

Review 3.  Cytokine signal transduction.

Authors:  T Kishimoto; T Taga; S Akira
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

Review 4.  Lymphocyte responses and cytokines.

Authors:  W E Paul; R A Seder
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

5.  Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts.

Authors:  R E Herrera; V P Sah; B O Williams; T P Mäkelä; R A Weinberg; T Jacks
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

6.  Interleukin-3 regulates the activity of the LYN protein-tyrosine kinase in myeloid-committed leukemic cell lines.

Authors:  T Torigoe; R O'Connor; D Santoli; J C Reed
Journal:  Blood       Date:  1992-08-01       Impact factor: 22.113

7.  Granulocyte colony-stimulating factor receptor signaling involves the formation of a three-component complex with Lyn and Syk protein-tyrosine kinases.

Authors:  S J Corey; A L Burkhardt; J B Bolen; R L Geahlen; L S Tkatch; D J Tweardy
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

8.  Regulation of the cell cycle machinery by oncogenic ras.

Authors:  J T Winston; S R Coats; Y Z Wang; W J Pledger
Journal:  Oncogene       Date:  1996-01-04       Impact factor: 9.867

Review 9.  Cytokine receptor signalling.

Authors:  J N Ihle
Journal:  Nature       Date:  1995-10-19       Impact factor: 49.962

10.  Functional and biochemical association of Hck with the LIF/IL-6 receptor signal transducing subunit gp130 in embryonic stem cells.

Authors:  M Ernst; D P Gearing; A R Dunn
Journal:  EMBO J       Date:  1994-04-01       Impact factor: 11.598

View more
  5 in total

Review 1.  JAK2 inhibitors: what's the true therapeutic potential?

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Blood Rev       Date:  2010-11-20       Impact factor: 8.250

Review 2.  JAK2 inhibitors: are they the solution?

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-05-04

Review 3.  Therapy with JAK2 inhibitors for myeloproliferative neoplasms.

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Hematol Oncol Clin North Am       Date:  2012-08-21       Impact factor: 3.722

Review 4.  Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One.

Authors:  Timothy W Corson; Nicholas Aberle; Craig M Crews
Journal:  ACS Chem Biol       Date:  2008-11-21       Impact factor: 5.100

5.  In silico Prediction on the PI3K/AKT/mTOR Pathway of the Antiproliferative Effect of O. joconostle in Breast Cancer Models.

Authors:  Alejandra Ortiz-González; Pedro Pablo González-Pérez; Maura Cárdenas-García; María Guadalupe Hernández-Linares
Journal:  Cancer Inform       Date:  2022-03-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.